- Prohealth - https://www.prohealth.com -

U of Utah Recruiting Fibromyalgia & FM/CFS Patients for Pregabalin Biomarker Study

Why does Lyrica® (generic name pregabalin) help some FM patients and not others?

The Department of Anesthesiology at the University of Utah [1], Salt Lake City, announced July 10 that it is seeking participants for a study to investigate Lyrica’s “effects on blood biomarkers” in patients with fibromyalgia or FM & chronic fatigue syndrome (ME/CFS).

Lyrica (pregabalin) is a prescription drug marketed by Pfizer that gained FDA approval in 2007* for treatment of fibromyalgia.

Study Details

According to the July 10 blood biomarkers study announcement:

• Researchers hope to learn more about why Lyrica is effective for some patients and not for others.

• Volunteers with fibromyalgia (FMS) or chronic fatigue syndrome and FMS who are not currently using Lyrica are needed to participate in this IRB-approved trial.

• Eligible volunteers will receive Lyrica for five weeks and a placebo for five weeks, and will be compensated for their time.

• For more information, contact Andrea White (andrea.white@hsc.utah.edu [2])
___
* As Pfizer’s Lyrica patents begin expiring, in October 2013, the $3.4 billion annual Lyrica market will be opening to ‘generic’ (generally lower price) versions of the drug, and as of July 5, the FDA approved marketing of a generic pregabalin product [3] by Lupin Pharmaceuticals.